• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by iRhythm Technologies Inc.

    1/12/26 5:03:48 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email
    S-8 POS 1 tm262849d12_s8pos.htm S-8 POS

     

     

    As filed with the U.S. Securities and Exchange Commission on January 12, 2026

     

    Registration No. 333-263066

    Registration No. 333-256762

    Registration No. 333-236838

    Registration No. 333-233033

    Registration No. 333-223351

    Registration No. 333-217077

    Registration No. 333-214203

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    POST-EFFECTIVE AMENDMENT NO. 1 TO
    FORM S-8 (No. 333-263066)

    POST-EFFECTIVE AMENDMENT NO. 1 TO
    FORM S-8 (No. 333-256762)

    POST-EFFECTIVE AMENDMENT NO. 1 TO
    FORM S-8 (No. 333-236838)

    POST-EFFECTIVE AMENDMENT NO. 1 TO
    FORM S-8 (No. 333-233033)

    POST-EFFECTIVE AMENDMENT NO. 1 TO
    FORM S-8 (No. 333-223351)

    POST-EFFECTIVE AMENDMENT NO. 1 TO
    FORM S-8 (No. 333-217077)

    POST-EFFECTIVE AMENDMENT NO. 2 TO
    FORM S-8 (No. 333-214203)

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    iRhythm Holdings, Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of
    incorporation or organization)

    39-2182599

    (I.R.S. Employer
    Identification Number)

     

    699 8th Street, Suite 600
    San Francisco, California 94103

    (Address of principal executive offices including Zip Code)

    2006 STOCK PLAN

    2016 EQUITY INCENTIVE PLAN

    2016 EMPLOYEE STOCK PURCHASE PLAN

    (Full title of the plans)

    Quentin S. Blackford

    Chief Executive Officer

    iRhythm Holdings, Inc.

    699 8th Street, Suite 600

    San Francisco, California 94103

    (650) 632-5700

    (Name, address, and telephone number, including area code, of agent for service)

    Copy to:

     

    Michael A Brown

    Julia Forbess

    Fenwick & West LLP

    555 California Street

    12th Floor

    San Francisco, California 94104

    (415) 875-2300

    Patrick Murphy

    Chief Legal Officer

    iRhythm Holdings, Inc.

    699 8th Street, Suite 600

    San Francisco, California 94103

    (650) 632-5700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x   Accelerated filer ¨
    Non-accelerated filer ¨   Smaller reporting company ¨
          Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    iRhythm Holdings, Inc., a Delaware corporation (the “Registrant”), files these Post-Effective Amendments to the following Registration Statements on Form S-8 (the “Registration Statements”) of iRhythm Technologies, Inc., a Delaware corporation (“Predecessor”), as the successor issuer to Predecessor in connection with the Predecessor’s implementation of a corporate holding company structure that resulted in the formation of a new parent holding company (the “Holding Company Transaction”):

     

    ·Registration Statements No. 333-256762, No. 333-236838, No. 333-233033, No. 333-223351 and No. 333-217077, as filed with the U.S. Securities and Exchange Commission (the “Commission”) on March 31, 2017, March 1, 2018, August 6, 2019, March 2, 2020, June 4, 2021 and February 28, 2022, respectively, each pertaining to the registration of securities of the Registrant issuable under Predecessor’s 2016 Equity Incentive Plan (the “2016 Plan”) and Predecessor’s 2016 Employee Stock Purchase Plan (the “ESPP”), respectively; and

     

    ·Registration Statement No. 333-263066, as filed with the Commission on October 21, 2016 (as amended October 26, 2016), pertaining to the registration of securities of the Registrant issuable under the 2016 Plan, the ESPP and Predecessor’s 2006 Equity Incentive Plan (the “2006 Plan,” and collectively with the 2016 Plan and the ESPP, the “Plans”), respectively.

     

    The Holding Company Transaction was completed on January 12, 2026 and was effected through a merger pursuant to the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of January 12, 2026, among iRhythm Holdings, Inc. (f/k/a LTCM Holdings, Inc.), Predecessor and LTCM Merger Sub, Inc., a Delaware corporation (“Merger Sub”). The Holding Company Transaction was conducted pursuant to Section 251(g) of the General Corporation Law of the State of Delaware, which provides for the formation of a holding company without a vote of the stockholders of the constituent corporation.

     

    Pursuant to the Holding Company Transaction, Predecessor merged with and into Merger Sub, a direct wholly-owned subsidiary of the Registrant, with Merger Sub continuing as the surviving entity and a direct wholly-owned subsidiary of the Registrant (the “Merger”). Upon the effectiveness of the Merger, each share of Predecessor common stock held immediately prior to the Merger automatically converted into a right to receive an equivalent corresponding share of common stock of the Registrant, par value $0.001 per share, such shares having the same designations, rights, powers and preferences and the qualifications, limitations and restrictions as the corresponding share of common stock of Predecessor being converted. Accordingly, upon consummation of the Holding Company Transaction, the current stockholders of Predecessor became stockholders of the Registrant. Further, pursuant to the Merger Agreement, as of the effectiveness of the Merger, the Plans and all award agreements granted pursuant thereto were amended as necessary to provide that any reference to Predecessor and to each share of Predecessor in such agreements shall be deemed to refer to the Registrant and to shares of common stock of the Registrant.

     

    Following the Holding Company Transaction, the Registrant is the successor issuer to Predecessor pursuant to Rule 414 under the Securities Act of 1933, as amended (the “Securities Act”), and Rule 12g-3(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As the successor issuer, the shares of the Registrant’s common stock are deemed to be registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Global Select Market under the symbol “IRTC.”

     

    In accordance with paragraph (d) of Rule 414 under the Securities Act, the Registrant, as the successor issuer to Predecessor, hereby expressly adopts the Registration Statements as its own registration statements (except as specifically amended by these Post-Effective Amendments) for all purposes of the Securities Act and the Exchange Act, and all securities registered under this registration statement will be securities of the Registrant rather than Predecessor. These Post-Effective Amendments shall become effective immediately upon filing with the Commission pursuant to Rule 462 under the Securities Act. Predecessor paid all registration fees at the time of filing of the Registration Statements.

     

    No additional securities are being registered hereby.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant hereby incorporates by reference into this Registration Statement the following documents filed with the Commission:

     

    (a)The Predecessor’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 20, 2025 (File No. 001-37918);

     

    (b)All reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Predecessor’s Annual Report referred to in (a) above (other than information in any Current Report on Form 8-K deemed to have been furnished and not filed in accordance with the rules of the Commission and, except as may be noted in any such Form 8-K, exhibits filed on such Form 8-K that are related to such information); and

     

    (c)The Registrant’s Registration Statement on Form 8-K, including the description of the Registrant’s Common Stock contained in Exhibit 4.1 thereto filed on January 12, 2026, including any amendments or reports filed for the purpose of updating such description.

     

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of the Registrant’s common stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicate that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Under no circumstances will any information filed under Items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

     

     

     

    Item 6. Indemnification of Directors and Officers.

     

    The Registrant’s amended and restated certificate of incorporation contains provisions that eliminate, to the maximum extent permitted by the General Corporation Law of the State of Delaware, the personal liability of the Registrant’s directors and executive officers for monetary damages for breach of their fiduciary duties as directors or officers. The Registrant’s amended and restated certificate of incorporation and bylaws provide that the Registrant must indemnify its directors and executive officers and may indemnify its employees and other agents to the fullest extent permitted by the General Corporation Law of the State of Delaware.

     

    Sections 145 and 102(b)(7) of the General Corporation Law of the State of Delaware provide that a corporation may indemnify any person made a party to an action by reason of the fact that he or she was a director, executive officer, employee or agent of the corporation, or is or was serving at the request of a corporation, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of an action by or in right of the corporation, no indemnification may generally be made in respect of any claim as to which such person is adjudged to be liable to the corporation.

     

    The Registrant has entered into indemnification agreements with its directors and executive officers in addition to the indemnification provided for in its amended and restated certificate of incorporation and bylaws and intends to enter into indemnification agreements with any new directors and executive officers in the future.

     

    The Registrant has purchased and intends to maintain insurance on behalf of each and any person who is or was a director or officer of the Registrant against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

     

    See also the undertakings set out in response to Item 9 herein.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

            Incorporated by Reference
    Exhibit Number   Exhibit Title   Form   File No.   Exhibit   Filing Date
    4.1   Amended and Restated Certificate of Incorporation.   8-K   001-37918   3.1   January 12, 2026
    4.2   Amended and Restated Bylaws.   8-K   001-37918   3.2   January 12, 2026
    4.3   2016 Equity Incentive Plan, as amended November 7, 2024, and related form agreements.   8-K   001-37918   10.1   November 11, 2024
    4.4   2016 Employee Stock Purchase Plan, as Amended February 26, 2019, and related form agreements.   10-Q   001-37918   10.1   December 23, 2019
    4.5   2006 Stock Plan and related form agreements.   S-1   333-213773   10.2   September 23, 2016
    5.1   Opinion of Fenwick & West LLP.   Filed herewith            
    23.1   Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.   Filed herewith            
    23.2   Consent of Fenwick & West LLP (included in Exhibit 5.1).   Filed herewith            
    24.1   Power of Attorney (contained on signature page hereto).   Filed herewith            

     

     

     

     

    Item 9. Undertakings.

     

    (a)The Registrant hereby undertakes:

     

    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and

     

    (iii)To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement.

     

    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these post-effective amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, California, on January 12, 2026.

     

        IRHYTHM HOLDINGS, INC.
         
      By: /s/ Quentin S. Blackford
        Quentin S. Blackford
        Chief Executive Officer

     

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Quentin S. Blackford and Daniel Wilson, and each of them, as his or her true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name   Position   Date
             
    /s/ Quentin S. Blackford   President, Chief Executive Officer and Director   January 12, 2026
    Quentin S. Blackford   (Principal Executive Officer)  
             
    /s/ Daniel Wilson   Chief Financial Officer   January 12, 2026
    Daniel Wilson   (Principal Financial Officer)  
             
    /s/ Marc Rosenbaum   Chief Accounting Officer   January 12, 2026
    Marc Rosenbaum   (Principal Accounting Officer)    
             
    /s/ Abhijit Y. Talwalkar   Director   January 12, 2026
    Abhijit Y. Talwalkar    
             
    /s/ C. Noel Bairey Merz, M.D.   Director   January 12, 2026
    C. Noel Bairey Merz, M.D.    
             
    /s/ Bruce G. Bodaken   Director   January 12, 2026
    Bruce G. Bodaken    
             
    /s/ Karen Ling   Director   January 12, 2026
    Karen Ling    
             
    /s/ Karen McGinnis   Director   January 12, 2026
    Karen McGinnis    
             
    /s/ Kevin O’Boyle   Director   January 12, 2026
    Kevin O’Boyle    
             
    /s/ Brian Yoor   Director   January 12, 2026
    Brian Yoor    

     

     

     

     

    Get the next $IRTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRTC

    DatePrice TargetRatingAnalyst
    1/5/2026$210.00In-line → Outperform
    Evercore ISI
    9/23/2025$185.00In-line
    Evercore ISI
    8/20/2025$200.00Buy
    BofA Securities
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    12/3/2024$86.00Equal Weight
    Wells Fargo
    10/4/2024$78.00Neutral
    Goldman
    6/20/2024$115.00Peer Perform → Outperform
    Wolfe Research
    12/11/2023$110.00Neutral → Buy
    Citigroup
    More analyst ratings

    $IRTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/5/24 11:59:44 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Patterson Chad bought $20,994 worth of shares (280 units at $74.98) and sold $224,876 worth of shares (3,012 units at $74.66), decreasing direct ownership by 7% to 37,133 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/5/24 5:35:18 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Blackford Quentin S. bought $997,644 worth of shares (9,755 units at $102.27), increasing direct ownership by 8% to 128,510 units (SEC Form 4) (Amendment)

    4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)

    12/6/23 7:08:38 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference. Recent Operational Highlights and Financial Outlook Anticipate full year 2025 revenue to exceed high end of previously stated guidance range of $740 million provided in October 2025, driven by record revenue unit volume during the fourth quarter 2025For full year 2026, expect revenue of approximately $870 million to $880 million, or approximat

    1/12/26 7:30:00 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference. iRhythm's management is scheduled to present on Monday, January 12, 2026, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Events and Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc.iRhythm is a leading digi

    12/29/25 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlight the Performance of iRhythm's Zio Long-Term Continuous Monitoring in an Asian Population

    iRhythm Technologies presented new data during the joint Asia Pacific Heart Rhythm Society (APHRS) and Japan Heart Rhythm Society (JHRS) scientific sessions.Large-scale analysis of more than 400,000 patients1 supports the consistency and generalizability of Zio long-term ECG monitoring (LTCM) performance across populations; median wear and analyzable time among patients identified as Asian (3.4% of the cohort) were comparable to those of non-Asian patients, and findings were consistent with Zio LTCM performance previously reported in the published CAMELOT2 and AVALON3 studies. SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced new dat

    11/21/25 8:10:00 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by iRhythm Technologies Inc.

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    12/3/25 4:35:58 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    CBO and CLO Murphy Patrick Michael sold $458,009 worth of shares (2,478 units at $184.83), decreasing direct ownership by 4% to 53,281 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    12/3/25 4:35:40 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    CHIEF MED/SCI OFCR EVP ADVTECH Turakhia Minang was granted 250 shares, increasing direct ownership by 0.60% to 41,643 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    12/2/25 6:34:35 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    iRhythm upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded iRhythm from In-line to Outperform and set a new price target of $210.00

    1/5/26 8:34:48 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on iRhythm with a new price target

    Evercore ISI initiated coverage of iRhythm with a rating of In-line and set a new price target of $185.00

    9/23/25 8:17:27 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    BofA Securities initiated coverage on iRhythm with a new price target

    BofA Securities initiated coverage of iRhythm with a rating of Buy and set a new price target of $200.00

    8/20/25 8:56:18 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    SEC Filings

    View All

    SEC Form S-8 POS filed by iRhythm Technologies Inc.

    S-8 POS - iRhythm Holdings, Inc. (0001388658) (Filer)

    1/12/26 5:03:48 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by iRhythm Technologies Inc.

    S-8 POS - iRhythm Holdings, Inc. (0001388658) (Filer)

    1/12/26 5:02:05 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by iRhythm Technologies Inc.

    S-8 POS - iRhythm Holdings, Inc. (0001388658) (Filer)

    1/12/26 5:00:08 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Leadership Updates

    Live Leadership Updates

    View All

    iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

    iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

    2/29/24 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Derrick Sung Joins Aerin Medical as Chief Financial Officer

    A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer

    11/20/23 9:00:00 AM ET
    $IRTC
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

    SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering

    6/6/23 9:00:39 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Financials

    Live finance-specific insights

    View All

    iRhythm Technologies Announces Third Quarter 2025 Financial Results

    SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $192.9 million, a 30.7% increase compared to third quarter 2024Gross margin of 71.1%, a 230-basis point increase compared to third quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $565.2 million as of September 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights

    10/30/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies to Report Third Quarter 2025 Financial Results on October 30, 2025

    SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, October 30, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leadin

    10/16/25 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Announces Second Quarter 2025 Financial Results

    SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue of $186.7 million, a 26.1% increase compared to second quarter 2024Gross margin of 71.2%, a 130-basis point increase compared to second quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $545.5 million as of June 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA Recent Operational Highlights

    7/31/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 12:54:21 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 9:52:49 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/7/24 4:05:49 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care